Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN) reported Q1 EPS of ($0.80), $0.33 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $40 thousand versus the consensus estimate of $100 thousand.

For earnings history and earnings-related data on Sonnet BioTherapeutics Holdings, Inc. (SONN) click here.